Debanjana Chatterjee
Stock Analyst at Jones Trading
(0.25)
# 4,056
Out of 4,829 analysts
8
Total ratings
25%
Success rate
-24.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVRD Tvardi Therapeutics | Initiates: Buy | $39 | $26.03 | +49.83% | 1 | Apr 28, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $30 | $12.50 | +140.00% | 2 | Mar 26, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Buy | $23 | $3.79 | +506.86% | 1 | Mar 13, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $42 | $3.35 | +1,153.73% | 1 | Jan 27, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Hold | n/a | $15.16 | - | 1 | Dec 11, 2024 | |
| PHVS Pharvaris | Initiates: Buy | $46 | $16.59 | +177.36% | 1 | Sep 19, 2024 | |
| NTLA Intellia Therapeutics | Initiates: Buy | $41 | $8.71 | +370.99% | 1 | Sep 17, 2024 |
Tvardi Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $39
Current: $26.03
Upside: +49.83%
KalVista Pharmaceuticals
Mar 26, 2025
Maintains: Buy
Price Target: $30
Current: $12.50
Upside: +140.00%
Contineum Therapeutics
Mar 13, 2025
Initiates: Buy
Price Target: $23
Current: $3.79
Upside: +506.86%
Sagimet Biosciences
Jan 27, 2025
Initiates: Buy
Price Target: $42
Current: $3.35
Upside: +1,153.73%
Spyre Therapeutics
Dec 11, 2024
Initiates: Hold
Price Target: n/a
Current: $15.16
Upside: -
Pharvaris
Sep 19, 2024
Initiates: Buy
Price Target: $46
Current: $16.59
Upside: +177.36%
Intellia Therapeutics
Sep 17, 2024
Initiates: Buy
Price Target: $41
Current: $8.71
Upside: +370.99%